-
Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance. Neuro Oncol. 2024 05 03; 26(5):965-974. View in:
Pubmed
-
Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results. Nat Med. 2023 07; 29(7):1728-1737. View in:
Pubmed
-
Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumors. Cancer. 2023 06 15; 129(12):1904-1918. View in:
Pubmed
-
Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study. Br J Dermatol. 2022 09; 187(3):401-410. View in:
Pubmed
-
Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy. Clin Cancer Res. 2021 11 01; 27(21):5993-6000. View in:
Pubmed
-
Rejection of benign melanocytic nevi by nevus-resident CD4+ T cells. Sci Adv. 2021 Jun; 7(26). View in:
Pubmed
-
Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations. Nat Cancer. 2021 05; 2(5):498-502. View in:
Pubmed
-
Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018. Oncologist. 2021 06; 26(6):514-522. View in:
Pubmed
-
Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. J Immunother Cancer. 2021 03; 9(3). View in:
Pubmed
-
Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting. Oncologist. 2021 01; 26(1):49-55. View in:
Pubmed
-
Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med. 2020 Aug; 26(8):1309. View in:
Pubmed
-
Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis. Circulation. 2020 06 16; 141(24):2031-2034. View in:
Pubmed
-
Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med. 2020 08; 26(8):1280-1284. View in:
Pubmed
-
Case 16-2020: A 47-Year-Old Woman with Recurrent Melanoma and Pulmonary Nodules. N Engl J Med. 2020 May 21; 382(21):2034-2043. View in:
Pubmed
-
Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J. 2020 05 07; 41(18):1733-1743. View in:
Pubmed
-
Acute Kidney Injury Following Encorafenib and Binimetinib for Metastatic Melanoma. Kidney Med. 2020 May-Jun; 2(3):373-375. View in:
Pubmed
-
Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis. J Am Coll Cardiol. 2020 02 11; 75(5):467-478. View in:
Pubmed
-
Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist. 2020 03; 25(3):e398-e404. View in:
Pubmed
-
Neurologic complications of melanoma. Cancer. 2020 02 01; 126(3):477-486. View in:
Pubmed
-
Dermatology consultation reduces interruption of oncologic management among hospitalized patients with immune-related adverse events: A retrospective cohort study. J Am Acad Dermatol. 2020 04; 82(4):994-996. View in:
Pubmed
-
Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. Eur J Endocrinol. 2019 Sep; 181(3):211-219. View in:
Pubmed
-
Concurrent therapy with immune checkpoint inhibitors and TNFa blockade in patients with gastrointestinal immune-related adverse events. J Immunother Cancer. 2019 08 22; 7(1):226. View in:
Pubmed
-
Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. Neurology. 2019 09 10; 93(11):e1093-e1103. View in:
Pubmed
-
Developments in the Space of New MAPK Pathway Inhibitors for BRAF-Mutant Melanoma. Clin Cancer Res. 2019 10 01; 25(19):5735-5742. View in:
Pubmed
-
Targeting Molecular Pathways in Intracranial Metastatic Disease. Front Oncol. 2019; 9:99. View in:
Pubmed
-
Antitumor response to microscopic melanoma in the gastric mucosa mimicking ipilimumab-induced gastritis. J Immunother Cancer. 2019 02 11; 7(1):41. View in:
Pubmed
-
From Puppy to Patient: Translational Oncology. JAMA Intern Med. 2019 01 01; 179(1):7-8. View in:
Pubmed
-
Response to Immune Checkpoint Antibodies: Not All Responses Are Created Equal. Clin Cancer Res. 2019 02 01; 25(3):910-911. View in:
Pubmed
-
Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. Eur J Cancer. 2018 11; 104:137-144. View in:
Pubmed
-
Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience. Semin Arthritis Rheum. 2019 06; 48(6):1127-1132. View in:
Pubmed
-
Sisu-The Ability to Keep Fighting After Most Would Quit. JAMA Oncol. 2018 10 01; 4(10):1329. View in:
Pubmed
-
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol. 2018 04 24; 71(16):1755-1764. View in:
Pubmed
-
Are we entering the era of combination therapy for melanoma? Melanoma Manag. 2017 Mar; 4(1):5-8. View in:
Pubmed
-
PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. Clin Cancer Res. 2017 Aug 01; 23(15):4270-4279. View in:
Pubmed
